217 related articles for article (PubMed ID: 24965046)
1. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2.
Doloff JC; Chen CS; Waxman DJ
Mol Cancer; 2014 Jun; 13():158. PubMed ID: 24965046
[TBL] [Abstract][Full Text] [Related]
2. Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model.
Wu J; Waxman DJ
Cancer Lett; 2014 Oct; 353(2):272-80. PubMed ID: 25069038
[TBL] [Abstract][Full Text] [Related]
3. Transcriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenografts.
Doloff JC; Waxman DJ
BMC Cancer; 2015 May; 15():375. PubMed ID: 25952672
[TBL] [Abstract][Full Text] [Related]
4. VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression.
Doloff JC; Waxman DJ
Cancer Res; 2012 Mar; 72(5):1103-15. PubMed ID: 22237627
[TBL] [Abstract][Full Text] [Related]
5. Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression.
Chen CS; Doloff JC; Waxman DJ
Neoplasia; 2014 Jan; 16(1):84-96. PubMed ID: 24563621
[TBL] [Abstract][Full Text] [Related]
6. Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators.
Wu J; Jordan M; Waxman DJ
BMC Cancer; 2016 Aug; 16():623. PubMed ID: 27515027
[TBL] [Abstract][Full Text] [Related]
7. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.
Du B; Waxman DJ
Cancer Lett; 2020 Feb; 470():170-180. PubMed ID: 31765733
[TBL] [Abstract][Full Text] [Related]
8. VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.
Patten SG; Adamcic U; Lacombe K; Minhas K; Skowronski K; Coomber BL
BMC Cancer; 2010 Dec; 10():683. PubMed ID: 21159176
[TBL] [Abstract][Full Text] [Related]
9. Type-I interferon signaling is essential for robust metronomic chemo-immunogenic tumor regression in murine breast cancer.
Vergato C; Doshi KA; Roblyer D; Waxman DJ
Cancer Res Commun; 2022 Apr; 2(4):246-257. PubMed ID: 36187936
[TBL] [Abstract][Full Text] [Related]
10. CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.
Jordan M; Waxman DJ
Cancer Lett; 2016 Apr; 373(1):88-96. PubMed ID: 26655275
[TBL] [Abstract][Full Text] [Related]
11. Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8
Wu J; Waxman DJ
Oncoimmunology; 2015 Apr; 4(4):e1005521. PubMed ID: 26137402
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib.
Ma J; Waxman DJ
Mol Cancer Ther; 2008 Jan; 7(1):79-89. PubMed ID: 18202011
[TBL] [Abstract][Full Text] [Related]
13. Repeated tumor oximetry to identify therapeutic window during metronomic cyclophosphamide treatment of 9L gliomas.
Mupparaju S; Hou H; Lariviere JP; Swartz H; Jounaidi Y; Khan N
Oncol Rep; 2011 Jul; 26(1):281-6. PubMed ID: 21503586
[TBL] [Abstract][Full Text] [Related]
14. Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.
Doloff JC; Khan N; Ma J; Demidenko E; Swartz HM; Jounaidi Y
Curr Cancer Drug Targets; 2009 Sep; 9(6):777-88. PubMed ID: 19754361
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.
Man S; Bocci G; Francia G; Green SK; Jothy S; Hanahan D; Bohlen P; Hicklin DJ; Bergers G; Kerbel RS
Cancer Res; 2002 May; 62(10):2731-5. PubMed ID: 12019144
[TBL] [Abstract][Full Text] [Related]
16. Enhanced anti-tumor and anti-angiogenic effects of metronomic cyclophosphamide combined with Endostar in a xenograft model of human lung cancer.
Wang R; Qin S; Chen Y; Li Y; Chen C; Wang Z; Zheng R; Wu Q
Oncol Rep; 2012 Aug; 28(2):439-45. PubMed ID: 22641525
[TBL] [Abstract][Full Text] [Related]
17. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo.
Tongu M; Harashima N; Monma H; Inao T; Yamada T; Kawauchi H; Harada M
Cancer Immunol Immunother; 2013 Feb; 62(2):383-91. PubMed ID: 22926062
[TBL] [Abstract][Full Text] [Related]
18. Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity.
Lai V; Neshat SY; Rakoski A; Pitingolo J; Doloff JC
Adv Drug Deliv Rev; 2021 Dec; 179():113920. PubMed ID: 34384826
[TBL] [Abstract][Full Text] [Related]
19. Metronomic trofosfamide inhibits progression of human lung cancer xenografts by exerting anti-angiogenic effects.
Klink T; Bela C; Stoelting S; Peters SO; Broll R; Wagner T
J Cancer Res Clin Oncol; 2006 Oct; 132(10):643-52. PubMed ID: 16761121
[TBL] [Abstract][Full Text] [Related]
20. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
Kerbel RS; Shaked Y
Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
